Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MUC1 is a transmembrane glycoprotein aberrantly glycosylated in many cancers, leading to the exposure of the Tn antigen (GalNAc-O-Ser/Thr). This Tn-MUC1 glycoform is a tumor-associated neoantigen, making it a target for immunotherapeutic strategies.
Antibody binding to Tn-MUC1 inhibits cancer cell growth/survival; CAR-T cell mediated killing of Tn-MUC1 expressing cells
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mucin 1 (Tn-glycoform) (MUC1 (Tn)).